LearnGlossaryMarketStocksSuperinvestorsSign in

TENX

Tenax Therapeutics, Inc.

Healthcare · $48M market cap

Verdict

We can't put a fair value on TENX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-48.9% a year✗
Sales growth-3.6% a year✗
Free cash flow growth—?
Return on invested capital-58.3%✗

Follow TENX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 31, 2026: 4 open-market purchases worth $3.0M. Why purchases matter

Purchases

ADAR1 Capital Management, LLC

Owns 10%+ · 2026-09-03

Bought

$1.6M

ADAR1 Capital Management, LLC

Owns 10%+ · 2026-09-02

Bought

$338K

ADAR1 Capital Management, LLC

Owns 10%+ · 2026-09-01

Bought

$322K

ADAR1 Capital Management, LLC

Owns 10%+ · 2026-08-31

Bought

$723K

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works